Navigation Links
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Date:4/24/2009

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab

NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&D Day for investors and financial analysts at The Yale Club of New York City.

The presentations highlighted significant areas of development across Micromet's BiTE antibody platform and included updates on:

  • BiTE antibody Blinatumomab -- a rapid path to market has been identified for Acute Lymphoblastic Leukemia (ALL) with a registration trial planned to begin in 2010. Dose escalation continues in the study of blinatumomab for non-Hodgkin's lymphoma, with final results expected to be reported at the American Society of Hematology meeting in December.

  • BiTE antibody MT110 -- data presented at this week's annual meeting of the American Association for Cancer Research (AACR) demonstrated MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture and in animal models. EpCAM is a target antigen that is highly and frequently expressed on many types of solid tumors. MT110 currently is in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer.

  • EGFR BiTE Antibody -- pre-clinical data presented at AACR demonstrated that BiTE antibodies developed from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) (panitumumab) were highly active against KRAS-and BRAF-mutated human colorectal cancer cell lines. Recent clinical studies have shown that patients with tumor cells harboring mu
    '/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
2. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
3. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
4. Micromet Key Events for 2009
5. Micromet Expands Committed Equity Financing Facility to $75 Million
6. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
7. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
8. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
10. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
11. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... than doubled time without tumor growth and reduced the ... with placebo- Only once-daily oral cancer treatment to directly ... tumor cell division and blood vessel growth- Phase III ... additional cancersEAST HANOVER, N.J., March 30 Novartis announced ...
... Laboratory Response Network (LRN), the national laboratory system charged ... its first decade at its national meeting in Orlando, ... of Public Health Laboratories (APHL), the Centers for Disease ... Investigation (FBI) to test for agents of bioterrorism, the ...
Cached Medicine Technology:Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 2Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 3Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 4Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 5Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 6Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 7Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 8Nation's Laboratory Response Network Marks First Decade of Protecting Public Health 2
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
(Date:7/9/2014)... A study published in the scientific journal Nature ... two researchers at Universit Laval, reveals that it is ... that involves rekindling pain so that it can subsequently ... to alleviate chronic pain. , The researchers from the ... en sant mentale de Qubec (IUSMQ) were inspired by ...
(Date:7/9/2014)... the Keck School of Medicine of the University ... lacking a specific component of the immune system ... complication of infection. The discovery suggests that blocking ... in human autoimmune and hyper-inflammatory diseases such as ... study was published online on June 23 in ...
(Date:7/8/2014)... Program in Memory Restoration has been awarded up to ... (DARPA) for a four -year project aiming to help ... of experts in neurosurgery, engineering, neurobiology, psychology and physics ... memory prosthesis in the brain. , Memory is the ... brain encode information, store it and retrieve it. Certain ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... of Trade Alerts on stocks making news today.Investors can view ... http://www.BeaconEquity.com/m Today,s Trade Alerts include: Humana Inc. (NYSE: ... Aetna Inc. (NYSE: AET ), CIGNA Corp. (NYSE: ... UNH ) and Universal American Corp. (NYSE: UAM ...
... , Improving rural sanitation by 65 percent could save ... scientists in Pennsylvania conclude in a new study on ... ACS, semi-monthly journal Environmental Science & Technology , ... experience the greatest savings in life. , In the ...
... CHICAGO, March 9 Illinois was the first state in ... station, police station and emergency medical facility that is required ... Abandoned Newborn Infant Protection Act to post a uniform sign ... informing persons that a newborn infant may be relinquished at ...
... FORT WORTH, Texas, March 9 Galderma Laboratories ... and Cetaphil(R) DailyAdvance(TM) Ultra Hydrating Lotion, have been ... Acceptance.The Seal of Acceptance criteria include review of ... well as ingredient and formulation data.The NEA Seal ...
... FoundationCHICAGO, March 9 Dental patients who have ... about how osteoporosis medications might affect their oral ... separate fact from fiction. The American Dental Association ... create the brochure, "Osteoporosis Medications and Your Dental ...
... Italian researchers report bedridden patients walked 24 hours after ... "bone cement" into lesions in patients whose cancer has ... to rise from their deathbeds and live the remainder ... presenting these findings Monday at the Society of Interventional ...
Cached Medicine News:Health News:Beacon Equity Issues Technical Trade Alerts on Healthcare Plan Stocks: HUM, WLP, AET, CI, UNH, UAM 2Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 2Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 3Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 4Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 5Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 6Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 7Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 8Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 9Health News:Save Abandoned Babies Foundation Commends Illinois Hospitals for Being 100% in Compliance in Displaying 'Safe Haven Signs' 2Health News:Three Cetaphil(R) Products Awarded National Eczema Association Seal of Acceptance 2Health News:ADA Informs Patients About Osteoporosis Medications and Oral Health 2Health News:ADA Informs Patients About Osteoporosis Medications and Oral Health 3Health News:Bone Cement Eases Pain of Late-Stage Cancers 2Health News:Bone Cement Eases Pain of Late-Stage Cancers 3
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: